- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00513201
Lyspro Insulin vs Regular Insulin in Cirrhotic Patients
August 7, 2007 updated by: University of Campania "Luigi Vanvitelli"
OBJECTIVE: To compare lispro insulin and regular insulin in the glycemic control of patients with liver cirrhosis and type 2 diabetes subjects.
METHODS: 108 patients with liver cirrhosis and type 2 diabetes were randomly treated with regular insulin or lispro.
After 122 weeks a cross-over was carried out and patients followed-up for 122 weeks.
Then, all patients received a standard breakfast of 145 kcal following 12 U.I. of regular insulin or lispro, and C-peptide and insulin serum levels were determined over 300 minutes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Naples, Italy, 80131
- Department of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 67 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Insulin-treated diabetes mellitus and liver cirrhosis
Exclusion Criteria:
- Oral hypoglycemic agents treated diabetes mellitus
- Liver cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Glycemic control in lyspro vs regular insulin treated patients
|
|
Glycemic control in lyspro vs regular insulin in cirrhotic patients
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Tolerance to treatment and reduced postprandial hypoglycemia episodes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Roberto Torella, MD, University of Campania "Luigi Vanvitelli"
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
August 7, 2007
First Submitted That Met QC Criteria
August 7, 2007
First Posted (Estimate)
August 8, 2007
Study Record Updates
Last Update Posted (Estimate)
August 8, 2007
Last Update Submitted That Met QC Criteria
August 7, 2007
Last Verified
August 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Second University of Naples
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.